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Abstract 
 Objective: To compare the clinical efficacy of ciprofloxacin vs 
ceftriaxone in terms of the proportion of children becoming afebrile in 96 
hours.                            
Study Design: Randomized controlled design study.                                                             
Place and Duration of Study: Department of Pediatrics, Holy Family 
Hospital, Rawalpindi from March 2010 to September 2010.                                                               
Methodology:  88 children who fulfilled the clinical criteria of having 
typhoid fever were included in the study. They came to the indoor and 
outdoor of the department. 44 patients were treated with injectable 
ciprofloxacin, while 44 were treated with injectable ceftriaxone.  
Results: The study included 88 patients with febrile illness who were 
suspected of having typhoid fever. The mean age was 8.3±1.94 years and 41 
(46.6%) were males. The mean weight was 24.7±6.3 kg. Only 15 (17%) used 
boiled water as a routine. 68 (77.3%) children in total became afebrile within 
96 hours and 20 (22.7%) failed to become afebrile in 96 hours. In the 
ciprofloxacin group, 25 (56.8%) patients became afebrile in 96 hours and 19 
(43.1%) failed to become afebrile in 96 hours. In the ceftriaxone group, 43 
(97.7%) patients became afebrile in 96 hours and 1 (2.3%) failed to become 
afebrile in 96 hours. The proportion of patients becoming afebrile within 96 
hours was significantly higher in the ceftriaxone group as compared to the 
ciprofloxacin group, p= 0.00. 
Conclusion: Ceftriaxone is more effective in children with typhoid fever in 
terms of greater proportion of children becoming afebrile in 96 hours.  
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Introduction 
 Typhoid fever, a communicable disease caused by the bacteria 
Salmonella typhoid, has been a major cause of significant morbidity and 
mortality since antiquity. Salmonellae are important gram-negative bacilli 
which cause a spectrum of characteristic clinical syndromes including 
gastroenteritis, enteric fever, bacteremia, endovascular infections, and focal 
infections such as osteomyelitis or abscesses. Enteric fever, also called 
typhoid fever or paratyphoid fever, is a systemic febrile illness that is most 
commonly caused by Salmonella typhi. Less frequently, it is caused by S. 
paratyphi A, S. typhi B, and S. paratyphi C. Even "nontyphoidal" 
Salmonellae may cause severe illness which is consistent with enteric fever. 
Complications are more common in untreated individuals and they include 
intestinal hemorrhage and perforation, or focal infection such as visceral 
abscesses. In the preantibiotic era, approximately 15 percent of afflicted 
individuals died, with survivors experiencing a prolonged illness lasting 
weeks and debilitation often-lasting months. Furthermore, approximately 10 
percent of untreated individuals relapse, while 1 to 4 percent becomes 
chronic carriers of the organism. 
 Pakistan has the third highest incidence rate of typhoid occurring in 
the general population, worldwide. Typhoid fever is a common presentation 
in pediatric clinics. In the western world, the disease is close to eradication 
levels. However, globally, there are at least 13 to 17 million cases resulting 
in 600000 deaths. Typhoid fever represents the 4th most common cause of 
death in Pakistan. It is transmitted by fecal oral root and by contamination of 
food and water. World Health Organization identifies typhoid as a serious 
public health problem. Its incidence is highest in children and young adults 
between 5-19 years old. WHO showed that the incidence of typhoid fever in 
Pakistani children aged 2-5 years was 573.2 per 100,000 persons per year. 
Also, similar incidence was seen in school going children and adolescents. 
The highest burden of disease is in children aged 2-15 years. Therefore, S 
Typhi represents the commonest cause of bacteraemia in this age group, and 
annual typhoid rates (confirmed by blood culture) in recent studies from 
India, Pakistan, and Indonesia range from 149 to as high as 573 cases per 
100 000 children. The definitive diagnosis of typhoid fever is made only on 
isolation of salmonella typhi from blood, stool, urine, bone marrow etc, in 
the presence of characteristics clinical features. The case fatality ratio is 10% 
in the absence of treatment, and less than 1% with the use of antibiotics. 
 Fluroquinolones i.e. Ciprofloxacin, are recommended as 1st line 
therapy for children and adults infected with sensitive as well as multidrug 
resistance, S. Typhi and paratyphi. Third generation cephalosporins i.e. 
Ceftriaxone, is also useful but their use is reserved for complicated cases   
Multidrug resistance (resistance to chloramphenicol, ampicillin, and co-
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trimoxazole) sequentially increased from 34% in 1999 to 66% in 2005. In a 
prospective study in North India, there was a gradual development of 
resistance to fluoroquinolones over the past 7 years. No resistance was 
observed to fluoroquinolones in 1999, while in 2005, 4.4% resistance was 
observed to sparfloxacin, 8.8% resistance to ofloxacin, and a high resistance, 
13%, to ciprofloxacin.  Keeping in mind drug resistance in the community, it 
can be questioned that either of these drugs have difference in efficacy in 
terms of sensitivity and resistance pattern and relapse. In addition, we plan to 
conduct a study to find out the clinical response in children with typhoid 
fever treated with ciprofloxacin vs ceftriaxone. Thus, the results of the study 
will enable paediatricians to choose the first line therapy for the treatment of 
enteric fever in similar setting. In this way, timely management of these 
children will reduce morbidity specifically and also reduce the burden on 
hospital clinics in general. 
 
 Methodology 
The study was conducted at Pediatric Department, Holy Family Hospital, 
Rawalpindi. Study was conducted over six months from 25th March 2010 to 
24th September 2010. A total of 88 patients with clinical diagnosis of typhoid 
fever were included in the study. 44 patients were treated with ciprofloxacin 
(Ciprofloxacin group), while 44 were treated with ceftriaxone (Ceftriaxone 
group). 
 
Consecutive (non-probability) Sampling Technique 
 Children 5-12 years old of both sexes having typhoid fever were 
included in the study. All those having current history of intake of oral or I/V 
antibiotics (third generation cephalosporins and quinolones) and absence of 
fever at the time of presentation were excluded. However, this was a 
Randomized Controlled Trial study. Patients fulfilling the study criteria were 
admitted in the pediatric ward of Holy Family Hospital and were randomly 
divided into two groups, A and B, based on random numbers. Group A was 
given Inj.Ciprofloxacin 10mg/kg I/V twice daily, while group B was given 
Inj. Ceftriaxone 70mg/kg I/V once daily for 7 days. Both groups were 
observed for the duration of becoming afebrile (96hrs). The investigation to 
be done during hospital stay was typhidot (IgM antibodies) from the 
designated laboratory with the standard kit. However, the results were 
verified by the consultant pathologist. Data was analyzed using SPSS (V10). 
Mean and standard deviation were calculated for quantitative variables i.e. 
age and duration of getting afebrile. Frequencies and percentages were 
calculated for qualitative variables i.e. gender and getting afebrile in 96 
hours. Consequently, chi-square test was used to compare the efficacy 
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(afebrile in 96hours) of both drugs. P-value < 0.05 was considered 
significant.             
 
Result 
 The study included 88 patients with febrile illness suspected of 
having typhoid fever on clinical grounds. Clinically, the patients had fever 
>37°C in the presence of at least one or more of the following sign and 
symptoms: Persistent headache, Abdominal pain or discomfort, Presence of 
splenomegaly / hepatomegaly, Rose spots on skin, vomiting, and no 
evidence of chest bowel urine or meningeal infection. Thus, all subjects were 
< 12 years of age. The age range was from 5 to 12 years with a mean age of 
8.3±1.94 years. 41 (46.6%) were males and 47 (53.4%) were females. The 
weight of the children ranged from 14 to 41 kg with a mean weight of 
24.7±6.3 kg. Furthermore, 15 (17%) used boiled water as a routine, while 73 
(83%) used unboiled water as a routine. 
 
Figure No 1. Histogram Showing Age Distribution of Study Group 
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Figure No 2. Histogram Showing Weight Distribution of Study Group 
 
Figure No 3. Pie Graph Showing Gender Distribution of Study Group 
 
Table 1. Gender Distribution in Study Groups 
Gender     Ciprofloxacin Ceftriaxone 
Male 24 (54.5%) 17 (38.6%) 
 Female 20 (45.5%) 27 (61.4%) 
 
Figure No 4. Water used Boiled and Non-boiled  
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Table 2. Chi square test comparing the frequency of patients becoming afebrile in 96 hours; 
ciprofloxacin versus ceftriaxone groups 
  
  
Antibiotic      group 
Total 
  
Ciproflox
acin Ceftriaxone 
Afebrile in 96 hours 
  
Yes 83% 
 25 43 68 
No  
17 % 19 1 20 
Total 44 44 88 
 
Chi-Square Tests 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 10.00. 
 
Discussion 
 Enteric fever is a common illness of children and young adults. This 
magnifies the socio-economic impact of the disease on the community. The 
industrialized and more prosperous countries have, to a great extent, controlled 
this illness by improving standards of public health; but the disease continues to 
be a major public health problem in less developed countries including 
Pakistan. Therefore, the emergence of drug resistant strains of Salmonella has 
made the treatment of enteric fever more difficult. The last 2 decades have also 
witnessed the appearance and spread of multidrug-resistant (MDR) strains of S. 
typhi. Infection with these strains is associated with longer duration of illness 
and higher morbidity and mortality. Thus, it is occurring at higher incidence 
throughout South Asia than previously thought particularly in younger children. 
Enteric fever is a significant problem in the preschool years. Among children, 
60% of cases are in the age group of 5 to 9 years, 27% between 2-5 years, and 
13% between age group of 0-2 years.208 After the emergence of 
chloramphenicol resistant Salmonella typhi strains, ciprofloxacin has become 
the choice of drugs for the treatment of typhoid fever even in the pediatric age 
group. 
The present study was carried out to compare the clinical efficacy of 
ciprofloxacin vs ceftriaxone in terms of the average time taken in the number 
of days for defevescence in the treatment of typhoid fever in children. 
 Value Df 
Asymp. Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 20.965(b) 1 .000     
Continuity 
Correction(a) 18.700 1 .000     
Likelihood Ratio 24.607 1 .000     
Fisher's Exact Test       .000 .000 
N of Valid Cases 88         
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Therefore, the study included 88 patients with febrile illness suspected of 
having typhoid fever. The mean age was 8.3±1.94 years and 41 (46.6%) 
were males. The mean weight was 24.7±6.3 kg. Only 15 (17%) used boiled 
water as a routine. 68 (77.3%) children in total became afebrile within 96 
hours, while 20 (22.7%) failed to become afebrile in 96 hours. In the 
ciprofloxacin group, 25 (56.8%) patients became afebrile in 96 hours and 19 
(43.1%) failed to become afebrile in 96 hours. In the ceftriaxone group, 43 
(97.7%) patients became afebrile in 96 hours and 1 (2.3%) failed to become 
afebrile in 96 hours. Therefore, the proportion of patients becoming afebrile 
within 96 hours was significantly higher in the ceftriaxone group as 
compared to the ciprofloxacin group, p= 0.00.  
 Our results thus differ from those of previous review, a summary of 
randomised controlled trials of enteric fever, which found fluoroquinolones 
to be superior to ceftriaxone for clinical failure and fever clearance times. 
Although these data suggest that fluoroquinolones had significantly lower 
fever clearance times compared with chloramphenicol, cefixime, and 
ceftriaxone, the analyses of fever clearance times must be interpreted with 
caution. The mean fever clearance times often follow a skewed 
distribution—although most patients clear fever quickly, some take much 
longer times—, so meta-analyses conducted using arithmetic means may not 
be accurate. However, the persistence of fever in some patients despite 
apparent clearance of S Typhi and S Paratyphi from the bloodstream has 
been attributed to the continued production of pyrogenic cytokines. This 
suggests that time taken to clear fever may not be an adequate measure of 
antibiotic efficacy. Consequently, they may not be an appropriate end point 
in typhoid therapy trials. Some investigators also did not specify whether 
clinical failures were excluded or included in the calculations of mean fever 
clearance time. This may be due to the irrational use of quinolones even in 
minor infections. Hence, most of this includes viral fevers. This has resulted 
in increasing the resistance of S typhi to quinolones in our country. 
 Appropriate treatment for enteric fever is a clinical and public health 
challenge, with rising levels of drug resistance and limited evidence for the 
use of newer agents, particularly for children. Large, well designed, and 
methodologically rigorous trials are needed to compare fluoroquinolones 
with first line antibiotics in community or outpatient settings. Hence, this 
reflects practice in low income countries, with accurate reporting of 
resistance data. Long term follow-up and monitoring of adverse effects are 
also required. Investigators must standardize definitions and time points of 
measurements of outcomes, particularly those with a subjective nature, such 
as clinical failure. In addition to objective studies of treatment efficacy and 
cost effectiveness, we need the evaluations of algorithmic approaches in the 
diagnosis and management of prolonged fever in children in regions where 
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typhoid is endemic. Such protocols will guide antibiotic use and may curb 
rising resistance.  A study at the Divisions of Clinical Medicine & 
Microbiology, National Institute of Cholera & Enteric Diseases (ICMR), 
Kolkata, India, evaluated the role of ceftriaxone therapy in bacteriologically 
confirmed MDR typhoid cases who did not respond to 12-14 days of 
ciprofloxacin therapy. Attempts have also been made to investigate the in 
vitro susceptibility of isolated S. typhi strains to chloramphenicol, 
ciprofloxacin, and ceftriaxone. A total of 140 children, aged 3-10 years, 
clinically diagnosed as having typhoid fever, without any clinical response 
after 12-14 days of ciprofloxacin therapy were screened for S. typhi by blood 
culture. In the bacteriologically positive children, the treatment was changed 
to intravenous ceftriaxone for 14 days. The isolated strains of S. typhi were 
tested for in vitro antimicrobial susceptibility. Clinical and bacteriological 
cure was observed with intravenous ceftriaxone therapy in all the 32 
bacteriologically positive patients. All isolated S. typhi strains were 
uniformly (100%) susceptible to ciprofloxacin and ceftriaxone. Thus, 50 
percent of the strains were resistant to chloramphenicol. The MIC values of 
chloramphenicol, ciprofloxacin, and ceftriaxone ranged between 125-500, 
0.0625-0.5 and < 0.0625 microgram/ml, respectively. The study indicates 
that although the S. typhi strains were susceptible to ciprofloxacin in vitro, 
the patients did not respond clinically and bacteriologically to ciprofloxacin 
therapy. Hence, ciprofloxacin may not represent a reliable and useful option 
for treating MDR typhoid fever; thus, ceftriaxone may be an effective 
alternative for the treatment of such cases. 
 Typhoid fever is widely prevalent in developing countries, with an 
annual burden of millions of cases globally. At Lady Reading Hospital, 
Peshawar, a study on drug resistance in enteric fever was carried out in 
Paediatric "A" Unit. Inclusion criterion was positive blood and/or bone 
marrow culture. In total, 50 patients had positive culture for salmonella 
(blood in 26 patients and bone marrow in 49 patients). Organism isolated 
were salmonella typhi in 49 cases and salmonella paratyphi A in one case. 
The single isolate of S paratyphi A was sensitive to all the antimicrobials 
tested except cotrimoxazole. Out of 49 isolates of S typhi, only 5 (10.2%) 
were sensitive to all the primary anti-typhoid antimicrobials, while 44 
(89.8%) were resistant to multiple drugs. All of the isolates here were fully 
sensitive to ciprofloxacin and ofloxacin, while sensitivity to third generation 
cephalosporins varied between 57% and 79%. Inspite of in vitro resistance, 
22 patients (44%) showed good clinical response to amoxycillin and 
chloramphenicol. In the remaining 28 patients (56%), response to the above 
drugs was poor, and they were started on ofloxacin (in children above 5 
years of age) or third generation cephalosporins. Consequently, the response 
of the patients to these drugs was good with defervescence within 8 days 
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after the start of treatment No significant effects of quinolones were noted in 
these children. They concluded that quinolones can be used in children above 
5 years of age in multidrug - resistant typhoid fever. The rapid spread of 
multidrug resistant (MDR) typhoid fever has posed a great challenge for the 
treatment of these cases all over the world today. After the emergence of 
chloramphenicol resistant Salmonella typhi strains, ciprofloxacin has become 
the drug of choice for the treatment of typhoid fever even in the paediatric 
age group. Thus, study at Kolkata, India, evaluated the role of ceftriaxone 
therapy in bacteriologically confirmed MDR typhoid cases that did not 
respond to 12-14 days of ciprofloxacin therapy. They included 140 children 
aged 3-10 years. Therefore, they found that ciprofloxacin might not represent 
a reliable and useful option for treating MDR typhoid fever. In addition, 
ceftriaxone may be an effective alternative for the treatment of such cases.i 
  
Conclusion 
 Ceftriaxone is more effective in children with typhoid fever in terms 
of greater proportion of children becoming afebrile in 96 hours 
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